Kenneth C Anderson

Kenneth C Anderson

UNVERIFIED PROFILE

Are you Kenneth C Anderson?   Register this Author

Register author
Kenneth C Anderson

Kenneth C Anderson

Publications by authors named "Kenneth C Anderson"

Are you Kenneth C Anderson?   Register this Author

100Publications

3641Reads

11Profile Views

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.

Blood Cancer J 2019 Aug 12;9(8):64. Epub 2019 Aug 12.

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0224-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690908PMC
August 2019

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.

Leukemia 2019 Aug 28. Epub 2019 Aug 28.

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0558-xDOI Listing
August 2019

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Expert Opin Biol Ther 2019 Jul 11:1-14. Epub 2019 Jul 11.

a LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute , Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1641196DOI Listing
July 2019

Insights into the management of older patients with multiple myeloma.

Clin Adv Hematol Oncol 2019 Jul;17(7):390-392

Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
July 2019

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Leukemia 2019 Jun 10. Epub 2019 Jun 10.

Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0498-5DOI Listing
June 2019

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.

Leukemia 2019 Apr 8. Epub 2019 Apr 8.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0467-zDOI Listing
April 2019

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Leukemia 2019 02 22;33(2):426-438. Epub 2018 Aug 22.

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0242-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367000PMC
February 2019

Contribution of Inhibition of Protein Catabolism in Myeloma.

Cancer J 2019 Jan/Feb;25(1):11-18

From the Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000349DOI Listing
January 2019

The power of proteasome inhibition in multiple myeloma.

Expert Rev Proteomics 2018 12 14;15(12):1033-1052. Epub 2018 Nov 14.

b Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14789450.2018.1543595DOI Listing
December 2018

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.

Cell Rep 2018 Dec;25(13):3693-3705.e6

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; VA Boston Healthcare System, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.12.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407615PMC
December 2018

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Ann Transl Med 2018 Dec;6(Suppl 2):S93

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.11.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330615PMC
December 2018

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):88-96

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.88DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245982PMC
November 2018

PRMT5 inhibitors on the (myeloma) road.

Oncotarget 2018 Nov 30;9(94):36646-36647. Epub 2018 Nov 30.

Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291180PMC
November 2018

Meaningful changes in end-of-life care among patients with myeloma.

Haematologica 2018 08 10;103(8):1380-1389. Epub 2018 May 10.

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.187609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068022PMC
August 2018

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Br J Haematol 2018 08 29;182(4):495-503. Epub 2018 May 29.

Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105456PMC
August 2018

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Front Immunol 2018 10;9:1821. Epub 2018 Aug 10.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, United States.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.01821
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.01821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095983PMC
August 2018

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Front Immunol 2018 10;9:1822. Epub 2018 Aug 10.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01822DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095980PMC
August 2018

The biological significance of histone modifiers in multiple myeloma: clinical applications.

Blood Cancer J 2018 08 22;8(9):83. Epub 2018 Aug 22.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0119-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127133PMC
August 2018

Promise of Immune Therapies in Multiple Myeloma.

J Oncol Pract 2018 07;14(7):411-413

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045492PMC
July 2018

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Future Oncol 2018 May 22;14(11):1035-1047. Epub 2017 Dec 22.

Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0616DOI Listing
May 2018

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Ann Hematol 2018 May 23;97(5):839-849. Epub 2018 Jan 23.

Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies', Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3237-5DOI Listing
May 2018

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Br J Haematol 2018 05 10;181(4):433-446. Epub 2018 May 10.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15116DOI Listing
May 2018

The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Nat Rev Clin Oncol 2018 04 9;15(4):219-233. Epub 2018 Jan 9.

Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.197DOI Listing
April 2018

Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Leuk Lymphoma 2018 03 13;59(3):542-561. Epub 2017 Jun 13.

a Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center , Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1337115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152877PMC
March 2018

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

J Oncol Pract 2018 02 28;14(2):129-133. Epub 2017 Nov 28.

Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; American Society of Clinical Oncology, Alexandria, VA; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.2017.028902
Publisher Site
http://dx.doi.org/10.1200/JOP.2017.028902DOI Listing
February 2018

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

J Clin Oncol 2018 01 28;36(3):283-299. Epub 2017 Nov 28.

Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.1734DOI Listing
January 2018

Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.

Cell Chem Biol 2017 12 19;24(12):1490-1500.e11. Epub 2017 Oct 19.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2017.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749250PMC
December 2017

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.

Expert Opin Pharmacother 2017 Dec 1;18(18):1975-1985. Epub 2017 Dec 1.

d Blood and Marrow Transplant Program , Roswell Park Cancer Institute , Buffalo , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1409207DOI Listing
December 2017

The proteasome and proteasome inhibitors in multiple myeloma.

Cancer Metastasis Rev 2017 12;36(4):561-584

Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-017-9707-8DOI Listing
December 2017

Targeting CD38 alleviates tumor-induced immunosuppression.

Oncotarget 2017 Dec 26;8(68):112166-112167. Epub 2017 Dec 26.

The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22992DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762499PMC
December 2017

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

J Clin Oncol 2017 Oct 25;35(29):3279-3289. Epub 2017 Jul 25.

Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652871PMC
October 2017

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

Oncotarget 2017 Oct 5;8(46):80109-80123. Epub 2017 Jul 5.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.19019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655183PMC
October 2017

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Clin Cancer Res 2017 Sep 25;23(17):5225-5237. Epub 2017 Apr 25.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581671PMC
September 2017

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Clin Cancer Res 2017 Aug 1;23(15):4290-4300. Epub 2017 Mar 1.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-3192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540790PMC
August 2017

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Clin Cancer Res 2017 Aug 7;23(15):4280-4289. Epub 2017 Mar 7.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540781PMC
August 2017

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.

Exp Hematol Oncol 2017 14;6:20. Epub 2017 Jul 14.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-017-0081-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512936PMC
July 2017

Multiple myeloma.

Nat Rev Dis Primers 2017 Jul 20;3:17046. Epub 2017 Jul 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrdp.2017.46DOI Listing
July 2017

Vision Statement for Multiple Myeloma: Future Directions.

Cancer Treat Res 2016;169:15-22

Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-40320-5_2DOI Listing
June 2017

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

N Engl J Med 2017 04;376(14):1311-1320

From the Institut Universitaire du Cancer de Toulouse-Oncopole (M.A., M.R., C.P., S.R., H.A.-L.) and Service d'Epidémiologie, Centre Hospitalier et Universitaire de Toulouse (V.L.-C.), Toulouse, Hôpital Haut-Lévêque, Bordeaux Pessac (C.H.), Centre Hospitalier et Universitaire la Miletrie, Poitiers (X.L.), Centre Hospitalier Le Bocage, Dijon (D.C.), Centre Hospitalier et Universitaire de Rennes, Rennes (M.E.), Hôpital St.-Louis (B.A., J.P.F.), Centre Hospitalier Universitaire, Hôpital St.-Antoine (L.G.), Institut Curie (C.M.), and Haute Autorité de Santé (J.-L.H.), Paris, Institut d'Hématologie de Basse Normandie, Centre Hospitalier et Universitaire de Caen, Caen (M.M.), Centre Hospitalier et Universitaire Henri Mondor, Creteil (K.B.), Hôpital Claude Huriez, Lille (T.F.), and Hôtel Dieu, Nantes (P.M.) - all in France; Institut Jules Bordet, Brussels (N. Meuleman); and Dana-Farber Cancer Institute, Boston (M.E.M., A.A.Z., E.A.W., N. Munshi, K.C.A., P.G.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201242PMC
April 2017

Should minimal residual disease negativity be the end point of myeloma therapy?

Blood Adv 2017 Mar 14;1(8):517-521. Epub 2017 Mar 14.

Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2016000117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728451PMC
March 2017

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Authors:
Kristin A Rand Chi Song Eric Dean Daniel J Serie Karen Curtin Xin Sheng Donglei Hu Carol Ann Huff Leon Bernal-Mizrachi Michael H Tomasson Sikander Ailawadhi Seema Singhal Karen Pawlish Edward S Peters Cathryn H Bock Alex Stram David J Van Den Berg Christopher K Edlund David V Conti Todd Zimmerman Amie E Hwang Scott Huntsman John Graff Ajay Nooka Yinfei Kong Silvana L Pregja Sonja I Berndt William J Blot John Carpten Graham Casey Lisa Chu W Ryan Diver Victoria L Stevens Michael R Lieber Phyllis J Goodman Anselm J M Hennis Ann W Hsing Jayesh Mehta Rick A Kittles Suzanne Kolb Eric A Klein Cristina Leske Adam B Murphy Barbara Nemesure Christine Neslund-Dudas Sara S Strom Ravi Vij Benjamin A Rybicki Janet L Stanford Lisa B Signorello John S Witte Christine B Ambrosone Parveen Bhatti Esther M John Leslie Bernstein Wei Zheng Andrew F Olshan Jennifer J Hu Regina G Ziegler Sarah J Nyante Elisa V Bandera Brenda M Birmann Sue A Ingles Michael F Press Djordje Atanackovic Martha J Glenn Lisa A Cannon-Albright Brandt Jones Guido Tricot Thomas G Martin Shaji K Kumar Jeffrey L Wolf Sandra L Deming Halverson Nathaniel Rothman Angela R Brooks-Wilson S Vincent Rajkumar Laurence N Kolonel Stephen J Chanock Susan L Slager Richard K Severson Nalini Janakiraman Howard R Terebelo Elizabeth E Brown Anneclaire J De Roos Ann F Mohrbacher Graham A Colditz Graham G Giles John J Spinelli Brian C Chiu Nikhil C Munshi Kenneth C Anderson Joan Levy Jeffrey A Zonder Robert Z Orlowski Sagar Lonial Nicola J Camp Celine M Vachon Elad Ziv Daniel O Stram Dennis J Hazelett Christopher A Haiman Wendy Cozen

Cancer Epidemiol Biomarkers Prev 2016 12 1;25(12):1609-1618. Epub 2016 Sep 1.

Keck School of Medicine of USC and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-1193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524541PMC
December 2016

Progress and Paradigms in Multiple Myeloma.

Clin Cancer Res 2016 Nov;22(22):5419-5427

Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-16-0625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300651PMC
November 2016

Immune Therapies in Multiple Myeloma.

Clin Cancer Res 2016 Nov;22(22):5453-5460

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0868DOI Listing
November 2016

AACR Cancer Progress Report 2016: Improving Lives Through Research.

Clin Cancer Res 2016 10 2;22(19):4759. Epub 2016 Oct 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2102DOI Listing
October 2016

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Blood 2016 09 14;128(12):1590-603. Epub 2016 Jul 14.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-03-707547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034739PMC
September 2016

A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.

Blood 2016 07 18;128(2):249-52. Epub 2016 May 18.

Medical Oncology, and LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; VA Boston Healthcare System, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-03-704460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946203PMC
July 2016

A new era of immune therapy in multiple myeloma.

Blood 2016 07;128(3):318-9

DANA-FARBER CANCER INSTITUTE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-06-719856DOI Listing
July 2016

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.

Mol Cancer Ther 2016 06 18;15(6):1364-75. Epub 2016 May 18.

Department of Experimental and Clinical Medicine, Magna Graecia University and Translational Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0985DOI Listing
June 2016

NCCN Guidelines Update for Multiple Myeloma.

J Natl Compr Canc Netw 2016 05;14(5 Suppl):675-7

Presented by Kenneth C. Anderson, MD, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
May 2016